MA56047A - Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting - Google Patents

Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting

Info

Publication number
MA56047A
MA56047A MA056047A MA56047A MA56047A MA 56047 A MA56047 A MA 56047A MA 056047 A MA056047 A MA 056047A MA 56047 A MA56047 A MA 56047A MA 56047 A MA56047 A MA 56047A
Authority
MA
Morocco
Prior art keywords
compositions
compounds
treatment
diseases associated
sting activity
Prior art date
Application number
MA056047A
Other languages
English (en)
Inventor
Jason Katz
William R Roush
Shankar Venkatraman
Original Assignee
Ifm Due Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ifm Due Inc filed Critical Ifm Due Inc
Publication of MA56047A publication Critical patent/MA56047A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA056047A 2019-05-29 2020-05-29 Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting MA56047A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962854288P 2019-05-29 2019-05-29

Publications (1)

Publication Number Publication Date
MA56047A true MA56047A (fr) 2022-04-06

Family

ID=71787083

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056047A MA56047A (fr) 2019-05-29 2020-05-29 Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting

Country Status (5)

Country Link
US (1) US20220227760A1 (fr)
EP (1) EP3976584A1 (fr)
JP (1) JP2022535743A (fr)
MA (1) MA56047A (fr)
WO (1) WO2020243519A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3817820A1 (fr) 2018-07-03 2021-05-12 IFM Due, Inc. Composés et compositions pour traiter des états pathologiques associés à une activité de sting
EP4134098A4 (fr) 2020-04-10 2024-05-15 ONO Pharmaceutical Co., Ltd. Méthode de cancérothérapie
EP4263531A2 (fr) * 2020-12-16 2023-10-25 IFM Due, Inc. Composés et compositions pour traiter des états pathologiques associés à une activité de sting
WO2022133046A2 (fr) * 2020-12-16 2022-06-23 Ifm Due, Inc. Composés et compositions pour traiter des états pathologiques associés à une activité de sting
JP2024502755A (ja) 2020-12-22 2024-01-23 アイエフエム デュー インコーポレイテッド がんを処置する方法
WO2022140403A1 (fr) 2020-12-22 2022-06-30 Ifm Due, Inc. Méthodes de traitement du cancer
EP4267129A1 (fr) 2020-12-22 2023-11-01 IFM Due, Inc. Méthodes de traitement du cancer
US20240041843A1 (en) 2020-12-22 2024-02-08 Ifm Due, Inc. Methods of treating cancer
EP4274824A1 (fr) 2021-01-08 2023-11-15 IFM Due, Inc. Composés hétérobicycliques ayant une urée ou un analogue et leurs compositions pour le traitement d'états associés à une activité de sting
TW202317087A (zh) 2021-08-10 2023-05-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關病況之化合物及組合物
WO2024064358A1 (fr) 2022-09-23 2024-03-28 Ifm Due, Inc. Composés et compositions pour le traitement d'affections associées à une activité de sting

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1318997T3 (da) * 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
PL2395004T3 (pl) * 2005-06-22 2016-08-31 Plexxikon Inc Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
CN102812023A (zh) * 2010-01-13 2012-12-05 韩国巴斯德研究所 抗感染吡啶并(1,2-a)嘧啶类
US9701631B2 (en) 2010-12-03 2017-07-11 The Trustees Of The University Of Pennsylvania TIP60 inhibitors
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
ES2754269T3 (es) 2013-05-18 2020-04-16 Aduro Biotech Inc Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
KR20160065858A (ko) 2013-10-21 2016-06-09 드렉셀유니버시티 만성 b형 간염 바이러스 감염을 치료하기 위한 스팅 효능제의 사용
US9580430B2 (en) * 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
CN107531690B (zh) * 2014-11-27 2020-11-06 基因泰克公司 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
WO2020099650A1 (fr) * 2018-11-15 2020-05-22 Institut Gustave Roussy Composés dérivés de madrasine, composition et leurs utilisations pour traiter le cancer
WO2020106736A1 (fr) * 2018-11-19 2020-05-28 Ifm Due, Inc. Composés et compositions pour traiter des états pathologiques associés à une activité de sting

Also Published As

Publication number Publication date
US20220227760A1 (en) 2022-07-21
WO2020243519A1 (fr) 2020-12-03
EP3976584A1 (fr) 2022-04-06
JP2022535743A (ja) 2022-08-10

Similar Documents

Publication Publication Date Title
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA56047A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
MA53096A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
MA44734A (fr) Composés et compositions destinés au traitement d'états associés à une activité de nlrp
MA53095A (fr) Composés et compositions pour traiter des états pathologiques associés à une activité de sting
MA56193A (fr) Composés et compositions pour traiter des états associés à une activité de sting
DK3906066T3 (da) Geneterapikonstruktioner til behandling af wilsons sygdom
MA55138A (fr) Composés et compositions pour traiter des états pathologiques associés à une activité de sting
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
EP3873335A4 (fr) Caractérisation de l'efficacité thérapeutique d'une neurostimulation
EP3755805A4 (fr) Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain
MA54753A (fr) Composés et compositions pour traiter des états pathologiques associés à une activité de sting
EP3963063A4 (fr) Compositions pour le traitement de la maladie de pompe
IL286711A (en) Interleukin-2 variants with modified biological activity
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
IL281809A (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
EP3606520A4 (fr) Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement des troubles coronaires
MA53562A (fr) Polythérapie destinée au traitement d'une maladie hépatique
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
MA55199A (fr) Leucine, acétyl leucine et analogues apparentés pour le traitement d'une maladie
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
EP3593803A4 (fr) Composés destinés au traitement de maladies causées par l'accumulation d'oxalate
EP3917910A4 (fr) Composés et compositions thérapeutiques
EP3923963A4 (fr) Traitement d'une insuffisance cardiaque